子宫内膜异位症的血管形成及抗血管形成治疗的研究进展
被引量:6
摘要
子宫内膜异位症(内异症)是好发于生育年龄妇女的常见疾病。近年来,对其发病机制的研究表明,内异症病灶的存活和生长依赖于足够的血液供应,血管形成是发病过程的关键环节之一。这一发现不仅为探索内异症发病机制提供了新线索,也为抗血管形成治疗提供了新思路。本文对近年来有关内异症血管形成及抗血管形成治疗的研究综述如下。
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
2007年第11期781-783,共3页
Chinese Journal of Obstetrics and Gynecology
参考文献30
-
1郎景和.子宫内膜异位症的研究与设想[J].中华妇产科杂志,2003,38(8):478-480. 被引量:531
-
2McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update,2000,6:45-55.
-
3Eggermont J, Donnez J, Casanas-Roux F, et al. Time course of pelvic endometriotic lesion revascularization in a nude mouse model Fertil Stefil, 2005,84:492-499.
-
4Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab, 2003,88:2889-2899.
-
5Nisolle M, Casanas-Roux F, Anaf V, et al. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril, 1993,59:681-684.
-
6Matsuzaki S, Canis M, Murakami T, et al. lmmunohistochemical analysis of the role of angiogenic status in the vasculature of peritoneal endometriosis. Fertil Steril, 2001,76:712-726.
-
7Oosterlynck DJ, Meuleman C, Sobis H, et al. Angiogenic activity of peritoneal fluid from women with endometriosis. Fertil Steril, 1993,59:778-782.
-
8Donnez J, Smoes P, Gillerot S,et al. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod, 1998,13 : 1686- 1690.
-
9Bourlev V, Volkov N, Pavlovitch S, et al. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction, 2006,132: 501-509.
-
10Gotefi G, Lucarini G, Filosa A, et al. Immunohistochemical analysis of vascular endothelial growth factor cellular expression in ovarian endometriomata. Fertil Steril,2004,81 : 1528-1533.
二级参考文献20
-
1Schindl M, Bimer P, Obermair A, et al. Increased microvessel density in adenomyosis uteri.Fertil Steril, 2001, 75(1):131-5.
-
2Khan KN, Masuzaki H, Fujishita A, et al. Immunoexpression of hepatocyte growth factor and c-Met receptor in the eutopic endometrium predicts the activity of ectopic endometrium.Fertil Steril, 2003, 79(1): 173-81.
-
3Ota H, Tanaka T. Stromal vascularization in the endometrium during adenomyosis. Microsc Res Tech, 2003, 60(4): 445-9.
-
4Guidi A J, Abu-Jawdeh G,Tognazzi K, et al.Expression of vascular permeability factor (vascular endothelial growth factor) and its recep-tors in endometrial carcinoma.Cancer,1996,78(3): 454-60.
-
5Goteri G, Lucarini G, Filosa A, et al. Immunohistochemical analysis of vascular endothelial growth factor cellular expression in ovarian endometriomata.Fertil Steril, 2004, 81(6):1528-33.
-
6Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorgienesis. Cell, 1996, 86(3):353-64.
-
7Fasciani A, Ambrogio G, Bocci G, et al. High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata. Mol Hum Reprod, 2000, 6(1):50-4.
-
8Tan X J, Lang JH, Liu DY, et al. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patient with endometriosis. Fertil Steril, 2002,78(1): 148-53.
-
9Huang JC, Papasakelariou C, Dawood MY. Epidermal growth factor and basic fibroblast growth factor in peritoneal fluid of women with endometriosis. Fertil Steril, 1996,65(5): 931-4.
-
10Loverro G, Maiorano E, Napoli A, et al. Transforming growth factor-beta 1 and insulin-like growth factor-1 expression in ovarian endometriotic cysts: a preliminary study. Int J Mol Med, 2001, 7(4): 423-9.
共引文献537
-
1李艳姣,邓新龙.子宫内膜异位症与女性生育力的相关性分析[J].医学信息(医学与计算机应用),2014,0(35):222-222.
-
2高艳薇.中西医结合治疗子宫内膜异位症[J].医学信息(医学与计算机应用),2014,0(16):507-507.
-
3刘海英,张作霞.米非司酮治疗子宫内膜异位症术后患者的临床研究[J].医学信息(医学与计算机应用),2014,0(3):105-105.
-
4齐岩,石红,葛琴.经阴道穿刺卵巢巧克力囊肿注入乙醇的疗效及血清CA-125观察[J].检验医学与临床,2006,3(2):79-79. 被引量:1
-
5羊俊茹.子宫内膜异位症手术治疗后复发65例临床分析[J].中外医疗,2008,27(16). 被引量:1
-
6黄晓萍.手术联合米非司酮对子宫内膜异位症的疗效观察[J].中外医疗,2008,27(21):30-31.
-
7胡柳,严红.切口子宫内膜异位症47例诊治分析[J].中国误诊学杂志,2009,9(4).
-
8路淑媛,周立娟,左娅.子宫内膜异位症治疗进展[J].中国现代药物应用,2009,3(6):126-127. 被引量:12
-
9袁春凤.89例子宫内膜异位症临床分析[J].中国实用医药,2007,2(9):57-58. 被引量:1
-
10韦静,贡丽霞.米非司酮在子宫内膜异位症腹腔镜手术后的应用[J].中国实用医药,2007,2(34):41-42. 被引量:6
同被引文献60
-
1朱慧莉,黄薇.VEGF在子宫内膜异位症发病机制中的作用[J].现代妇产科进展,2006,15(9):678-680. 被引量:8
-
2徐一鸣,濮德敏.内皮细胞抑素与子宫内膜异位症[J].中国优生与遗传杂志,2006,14(10):116-118. 被引量:1
-
3石一复.子宫内膜异位症的诊断与治疗现状[J].中华妇产科杂志,1996,31(10):579-581. 被引量:165
-
4王蕾,孙祖越,曹霖.血管生成与女性生殖系统疾患关系探讨[J].生殖与避孕,2007,27(1):52-55. 被引量:1
-
5张燕,孟元光,赵亚力,韩为东.肿瘤转移相关因子在子宫内膜异位症中的研究[J].国外医学(妇产科学分册),2007,34(4):282-284. 被引量:4
-
6董晓秋,王璐璐,毕伟,金钟男.卵巢巧克力囊肿无水乙醇硬化治疗前后卵巢功能的变化[J].中国超声医学杂志,2007,23(12):939-942. 被引量:12
-
7May CA,Ohlmann AV,Hammmes H. Proteins with an endostatin-like domain in a mouse model of oxygen-induced retinopathy[J].Experimental Eye research,2006,(02):341-348.
-
8Tan XY,Lang JH,Liu DY. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis[J].Fertility and Sterility,2002,(01):148-153.
-
9Absenger Y,Hess-Stumpp H,Kreft B. Cyr61,a deregulated gene in endometriosis[J].Molecular Human Reproduction,2006,(06):339-407.
-
10Nomas AS,Koide N,Hassan F. Thalidomide inhibits lipopolysaccharide-induced tunor necrosis factor-α production via down-regulation of MyD88 expression[J].Innatc Immun,2009,(01):33-41.
引证文献6
-
1李颖仪,黄妍.子宫内膜异位症药物治疗的分类与进展[J].北方药学,2011,8(12):13-13. 被引量:2
-
2姚爱静(综述),高大为(审校),李青,岳建华.子宫内膜异位症抑制血管形成因子与治疗的研究进展[J].医学临床研究,2012,29(3):566-568.
-
3狄文.内异症的相关进展[J].中华妇产科杂志,2013,48(4):279-283. 被引量:8
-
4李静,宋玉霞,王志红,刘月华.小金胶囊联合戈舍瑞林治疗子宫内膜异位症的临床研究[J].现代药物与临床,2021,36(6):1176-1180. 被引量:16
-
5刘淑真,彭佳华,梁瑞宁.中药有效成分干预子宫内膜异位症的实验研究进展[J].时珍国医国药,2023,34(4):954-957. 被引量:1
-
6姜珊珊,董晓秋,王璐璐,王思明,邵小慧.卵巢巧克力囊肿介入治疗前后血清IL-6、JunB、beta-1、4-GalT-Ⅰ的表达差异[J].中国超声医学杂志,2014,30(10):917-920. 被引量:5
二级引证文献32
-
1朱琳,颜士杰,沙玉成.血清和腹腔液中CA_(125)、TNF-α与子宫内膜异位症患者的相关性研究[J].中国妇幼保健,2014,29(8):1196-1198. 被引量:21
-
2冯翰.无水乙醇配伍曼月乐治疗复发性卵巢巧克力囊肿[J].中国现代医生,2014,52(10):130-131. 被引量:2
-
3汪艳丽.手术后口服小剂量米非司酮治疗子宫内膜异位症的近期疗效和副作用的初步研究[J].中国实用医药,2014,9(10):156-157. 被引量:6
-
4贾继刚,杨益森.不同类型盆腔深部浸润型子宫内膜异位症的疼痛特点及疗效分析[J].四川医学,2014,35(9):1135-1138. 被引量:3
-
5李凤英,王艳香,宋敏.米非司酮治疗子宫内膜异位症患者的临床观察[J].中国民康医学,2015,27(5):16-17. 被引量:2
-
6王菲,崔宏伟.子宫内膜异位症患者血清和腹腔液CA-125抗原、血管内皮生长因子水平的相关性研究[J].中国医师进修杂志,2015,38(9):664-667. 被引量:5
-
7李富琴,申玉红,张钊.腹腔镜保守性手术对内异症合并不孕患者的疗效分析[J].中国实用医药,2015,10(24):115-116.
-
8潘芳莉,罗莉.子宫内膜异位症与血清、腹腔液中CA125、TNF-α的相关性[J].临床血液学杂志(输血与检验),2017,30(4):625-627. 被引量:2
-
9马友香.个体化护理对子宫内膜异位症患者术前治疗效能感及术后服药依从性的影响[J].当代护士(下旬刊),2017,24(12):60-62. 被引量:3
-
10董静,王金会.深部浸润型子宫内膜异位症的临床症状和妇科检查价值评估研究[J].中国性科学,2018,27(2):41-44. 被引量:18
-
1贾卡,李进.抗血管形成靶向药物的研究进展[J].癌症,2008,27(4):442-446. 被引量:12
-
2林功标,肖健云.实体瘤治疗模式的展望[J].医学与哲学,2000,21(12):25-26.
-
3马春晓,徐国本.肿瘤血管形成和脑膜瘤[J].河南肿瘤学杂志,2003,16(6):456-458.
-
4谭先杰,潘凌亚.妇科肿瘤的血管形成和抗血管形成治疗研究进展[J].基础医学与临床,2004,24(3):252-257. 被引量:5
-
5马春燕,王振国.重组人血管内皮抑制素注射液治疗恶性肿瘤的作用机制及临床研究进展[J].中华临床医师杂志(电子版),2013,7(16):115-116. 被引量:6
-
6汤秀红.中药制剂抗肿瘤血管形成的基础研究现状与进展[J].吉林中医药,2010,30(9):825-828. 被引量:5
-
7李书芹,杨志勇,季艳霞,刘峥,贾军刚,万良刚.沙立度胺抑制MCF-7和MDA-MB-231细胞增殖的体外实验[J].河北医科大学学报,2008,29(5):660-661. 被引量:1
-
8佟喜勤,姜虹,曹秀明.p170、GSTπ、ToPoⅡ在肺癌中的表达及其临床意义[J].黑龙江医药,2001,14(4):327-328.
-
9杨志勇,李书芹,季艳霞,李海燕,张振军,贾军刚.沙立度胺抑制乳腺癌细胞增殖的体外实验[J].癌变·畸变·突变,2008,20(2):93-95.
-
10华馥,任慕兰.子宫内膜异位症的血管形成机制研究[J].国际妇产科学杂志,2008,35(5):313-316. 被引量:3